TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9084888
Drug: Oral ozagrel
Normalized name: Ozagrel
DrugBank: Ozagrel (DB12017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ozagrel tablet
Study: 8125395
Drug: Enteral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutritional support in conjunction with radiotherapy or chemotherapy
Study: 3234516
Drug: Turbuhaler (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (multiple dose powder inhaler)
Study: 29315168
Drug: Aerobic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training regimen of 72 supervised treadmill walking sessions delivered thrice weekly for 24 consecutive weeks
Study: 19114389
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplements and low n-6 PUFA cooking oils and spreads
Study: 10978947
Drug: Bismuth-based treatment
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based treatment (colloidal bismuth subcitrate 120 mg qid plus metronidazole 250 mg qid plus tetracycline 500 mg qid)
Study: 10978947
Drug: Bismuth-based treatment
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based treatment
Study: 1442450
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg, 2x/day)
Study: 31602573
Drug: AG200‐15 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200‐15 patch (N=78)
Study: 31602573
Drug: Xulane patch
Normalized name: Xulane
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xulane patch (N=77)
Study: 28949010
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks until 37 weeks or delivery
Study: 22024310
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg oral on day 1, 10 mg/day oral on days 2-4) with palonosetron (0.25 mg IV) and dexamethasone (20 mg IV)
Study: 22024310
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg oral on day 1, 80 mg oral on days 2-3) with palonosetron (0.25 mg IV) and dexamethasone (12 mg IV)
Study: 2661606
Drug: Amantadine 200
Normalized name: amantadine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 200 mg/day
Study: 11886025
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (CBT), 16 sessions
Study: 7616988
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg zidovudine immediately
Study: 7616988
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg zidovudine immediately
Study: 7616988
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy (placebo until CD4 < 500)
Study: 31376908
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg daily)
Study: 18620849
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intra-nasal midazolam
Study: 1941407
Drug: Bovine milk
Normalized name: Bovine Milk Plasma
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine milk protein preparation (BMP)
Study: 29933530
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine comprehensive therapy
Study: 29933530
Drug: Modern Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern Western Medicine treatment
Study: 10757273
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (200 mg)
Study: 10757273
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (200 mg)
Study: 20964499
Drug: Moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300 mg/day)
Study: 9023788
Drug: Fluoxetine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (200 mg/day)
Study: 1890934
Drug: Purified sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified sulfur (0.5-1 g mixed with 0.25 g of glucose, administered every 2-3 hours before irradiation)
Study: 6410897
Drug: Acidophilus milk
Normalized name: ACIDOPHILUS
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidophilus milk (240 ml, three times a day for 2 weeks)
Study: 29960810
Drug: Probiotic (PR)
Normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (PR) group received a probiotic formulation containing Bifidobacterium breve BR03 and B. breve B632 for 3 months.
Study: 29960810
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) group, received no active treatment.
Study: 27323614
Drug: Compound Sodium
Normalized name: SODIUM CHLORIDE 6 g in 1 L / SODIUM LACTATE 3.22 g in 1 L / POTASSIUM CHLORIDE 400 mg in 1 L / CALCIUM CHLORIDE 270 mg in 1 L INTRAVENOUS INJECTION, SOLUTION [COMPOUND SODIUM LACTATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Sodium Chloride Injection (Control)
Study: 25137874
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 to 320 mg/day (n = 18)
Study: 25137874
Drug: Non-renin-angiotensin-aldosterone-system blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-renin-angiotensin-aldosterone-system blocking antihypertensive agents (control, n = 15)
Study: 20146169
Drug: Atorvastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 20 mg daily
Study: 20146169
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg daily
Study: 17909315
Drug: Subunit-boosted vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit-boosted vaccine
Study: 17909315
Drug: ogp160-boosted vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ogp160-boosted vaccine
Study: 17909315
Drug: gp120 B/E-boosted
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp120 B/E-boosted vaccine
Study: 16184581
Drug: Caffeine 400
Normalized name: caffeine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 400 mg administered 30 min prior to sleep
Study: 16184581
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered prior to sleep
Study: 22677762
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of insulin
Study: 22677762
Drug: Frequent (every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent (every 3h) subcutaneous injections of insulin
Study: 11817991
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment with concomitant benazepril therapy
Study: 11817991
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment without benazepril
Study: 8785399
Drug: Cyclosporine (CsA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA; 4 to 5 mg/kg per day)
Study: 8785399
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 to 30 mg daily)
Study: 6222756
Drug: I% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: I% metronidazole cream
Study: 9377615
Drug: Placebo (cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cream base)
Study: 29121350
Drug: Individualized FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized FSH dosing (450/225 IU for RCT1, 100 IU for RCT2)
Study: 29121350
Drug: Standard FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard FSH dosing (150 IU)
Study: 29121350
Drug: Individualized FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized FSH dosing
Study: 25639994
Drug: STEP (Specialized
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEP (Specialized Treatment Early in Psychosis)
Study: 17690015
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group 2).
Study: 6115730
Drug: Propranolol 10
Normalized name: propranolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 10 mg
Study: 2347652
Drug: Org 10172
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 10172 administered as a single intravenous bolus of 2400 anti‐Xa units at start of dialysis
Study: 2347652
Drug: Org 10172
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 10172 administered as a single bolus of 3200 anti‐Xa units at start of dialysis
Study: 2347652
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (3250‐4750 I.U. heparin at start of hemodialysis followed by continuous infusion of 2000‐2700 I.U. per hour)
Study: 2347652
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including Org 10172 and heparin)
Study: 486891
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 60 ml of sodium iothalamate 70%
Study: 486891
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of a larger dose of contrast agent
Study: 25453380
Drug: Frozen Hoodia
Normalized name: HOODIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen Hoodia (3 g)
Study: 17561009
Drug: Oral norethisterone
Normalized name: ethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral norethisterone acetate 1 mg/day + 17beta-estradiol 2 mg/day
Study: 15709712
Drug: Allogeneic irradiated
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic irradiated RCC-cell-line cells (ACHN-IL-2) admixed with autologous metastatic formalin-treated tumour cells, administered subcutaneously, 4-20 injections (mean 10 +/- 4), average of 92 x 10(6) ACHN-IL-2 transfected cells.
Study: 15709712
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard immunotherapy without the vaccine.
Study: 8273793
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg/day continuously for 5 years (Group A)
Study: 8273793
Drug: Seasonal prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal prophylactic treatment with ranitidine 300 mg/day for 8 weeks in spring and fall (Group B)
Study: 3054641
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) - one swallow tablet 4 times a day (11 patients)
Study: 3054641
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) - two swallow tablets twice daily (16 patients)
Study: 3054641
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) - two buffered swallow tablets twice daily (14 patients)
Study: 3054641
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) - two chew tablets twice daily (22 patients)
Study: 3054641
Drug: Patients rebiopsied
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients rebiopsied 44‐137 days following treatment
Study: 19954715
Drug: Equasym Retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equasym Retard 20 mg
Study: 19954715
Drug: Medikinet retard
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medikinet retard 20 mg
Study: 17406138
Drug: Enuretic alarm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enuretic alarm therapy (group 1)
Study: 17406138
Drug: Desmopressin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin therapy (group 2)
Study: 17406138
Drug: Enuretic alarm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enuretic alarm therapy as secondary treatment (group 3)
Study: 14993506
Drug: High dialysis
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dialysis dose (HDD) group (target Kt/V(eq) of 1.4)
Study: 14993506
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein (HP) diet (1.3 g/kg of ideal body weight/day)
Study: 14993506
Drug: Regular protein
Normalized name: PROTEIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular protein (RP) diet (0.9 g/kg/day)
Study: 14993506
Drug: High dialysis
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dialysis dose (HDD) group
Study: 14993506
Drug: Regular dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dialysis dose (RDD) group
Study: 14993506
Drug: Increasing dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing dialysis dose
Study: 12144582
Drug: Famotidine 10
Normalized name: famotidine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 10 mg
Study: 9258137
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg oral desmopressin
Study: 9258137
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg oral desmopressin
Study: 9258137
Drug: 600 mcg
Normalized name: Biotin 600 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mcg oral desmopressin
Study: 25977408
Drug: 4-mg nicotine
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg nicotine lozenges
Study: 20059357
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine (TDV), 3 injections at months 0, 4, and 12-15
Study: 20059357
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine (TDV), 2 injections at months 4 and 12-15
Study: 20059357
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine (TDV)
Study: 15679762
Drug: Mesalazine pellets
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine pellets (1.5 g/day in three doses)
Study: 15679762
Drug: Mesalazine tablets
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine tablets (1.5 g/day in three doses)
Study: 10225572
Drug: 500 mg/10
Normalized name: amikacin 500 mg/100 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/10 mL oral suspension
Study: 10225572
Drug: 500 mg/10
Normalized name: amikacin 500 mg/100 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/10 mL suspension (fasted)
Study: 10225572
Drug: 500 mg/5
Normalized name: Liquid C, 500 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/5 mL suspension (fasted)
Study: 10225572
Drug: 500 mg/10
Normalized name: amikacin 500 mg/100 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/10 mL suspension (fed)
Study: 2245092
Drug: Ibuprofen-codeine combination
Normalized name: codeine / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-codeine combination
Study: 639430
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg piretanide
Study: 26228672
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atorvastatin 40 mg and ezetimibe 10 mg
Study: 26228672
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (PS) added to atorvastatin therapy
Study: 26228672
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (PS) added to combined therapy
Study: 20046230
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (aspirin 100 mg)
Study: 20046230
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antiplatelet and anticoagulation therapy (target INR: 2.0‐3.0; mean 2.4+/‐0.3)
Study: 29330312
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (aspirin)
Study: 11405833
Drug: High-intensity laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity laser treatment
Study: 9210608
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terlipressin (1-2 mg, i.v. bolus) with ANP (35 ng/kg, i.v. bolus followed by 15 ng x kg(‐1) x min(‐1) for 60 min)
Study: 9210608
Drug: Terlipressin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin alone (1-2 mg, i.v. bolus)
Study: 7957341
Drug: Chemotherapy (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (after PAC or CAC therapy)
Study: 29333870
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual daily activities)
Study: 22682723
Drug: 24/4 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24/4 regimen (20 mcg ethinyl estradiol and 1 mg norethindrone acetate)
Study: 22682723
Drug: 21/7 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21/7 regimen (20 mcg ethinyl estradiol and 1 mg norethindrone acetate)
Study: 15593189
Drug: OPC‐28326 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC‐28326 40 mg
Study: 15593189
Drug: OPC‐28326 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC‐28326 10 mg
Study: 11340365
Drug: Intranasal CCK-8
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal CCK-8
Study: 3036715
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg five times daily) for seven days
Study: 3036715
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (10 mg/kg three times daily) combined with prednisolone (0.7 mg/kg daily) for ten days
Study: 27005766
Drug: TABLETS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TABLETS intervention
Study: 24748531
Drug: CAF +
Normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAF + CHO (6 mg kg(-1) BW caffeine and 0.8 g kg(-1) BW carbohydrate)
Study: 17012983
Drug: Levetiracetam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (mean maximum dosage 862.50±279.19 mg/day)
Study: 31706345
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (twice per week for 12 sessions at specified acupoints)
Study: 25275577
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine (bolus 1.5 mg/kg at induction, then infusion at 2 mg/kg/h, stopped 2 hours after surgery)
Study: 25493600
Drug: Daily infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily infant nevirapine
Study: 12934987
Drug: Oral-loaded divalproex
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-loaded divalproex (20 or 30 mg/kg/day on days 1 and 2 followed by 20 mg/kg/day)
Study: 12934987
Drug: Oral-loaded divalproex
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-loaded divalproex
Study: 12934987
Drug: Standard-titration divalproex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-titration divalproex
Study: 8602748
Drug: Anticoagulants (international
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (international normalized ratio range, 2.8-4.8)
Study: 1394813
Drug: Early instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early instillation of Adriamycin with oral administration of 5-fluorouracil (Group B)
Study: 1394813
Drug: Delayed instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed instillation of Adriamycin with oral administration of 5-fluorouracil (Group D)
Study: 2983151
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy and oral Levamisole
Study: 2983151
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy only
Study: 30213449
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus androgen deprivation therapy
Study: 28627930
Drug: Fenofibrate 100
Normalized name: fenofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 100 mg
Study: 25864750
Drug: Iontophoresis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis of the Chinese drug
Study: 23524368
Drug: Structured injury
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured injury prevention program performed twice weekly for the entirety of the season (58 prevention sessions)
Study: 17877674
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (50 micrograms)
Study: 12006420
Drug: Formoterol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (12 microg twice daily)
Study: 6367635
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate lozenges (23 mg, dissolved every 2 hours after an initial double dose)